EC signs 3rd contract with BioNTech-Pfizer for additional 1.8BN doses

The European Commission (EC) signed on May 20 a third contract with pharmaceutical companies BioNTech and Pfizer, reserving an additional 1.8 billion doses of vaccine against Covid-19 on behalf of all EU member states, between end 2021 to 2023, the EC said.

It will allow for the purchase of 900 million doses of the current vaccine and of a vaccine adapted to variants, with the option to purchase an additional 900 million doses.

The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU.

It also stipulates that, from the start of the supply in 2022, the delivery to the EU is guaranteed.

“Thanks to the well-established cooperation with the companies under the current contracts and arrangements put in place, timely deliveries of the doses are ensured,” the EC said.

The possibility for EU countries to resell or donate doses to countries in need outside the EU or through the COVAX Facility has been reinforced, contributing to a global and fair access to the vaccine across the world, the Commission said.

This new contract will strengthen the EU vaccine production capacity thus allowing to serve other markets across the world, the statement said.

European Commission President Ursula von der Leyen, said: “With our signature, the new contract is now in force, which is good news for our long term fight to protect European citizens against the virus and its variants.

“Production and delivery in the EU of up to 1.8 billion doses are guaranteed.  Potential contracts with other manufacturers will follow the same model, to the benefit of all,” Von der Leyen said.

Stella Kyriakides, European Commissioner for Health and Food Safety, said: “We need to be one step ahead of the virus.

“This means having access to adapted vaccines to protect us against the threat of variants, booster vaccines to prolong immunity, as well as protecting our younger population. Our focus is a priority on technologies that have proven their worth, like mRNA vaccines, but we keep our options open,” Kyriakides said.

“The past months have clearly demonstrated the need to have access to a broad portfolio of vaccines and different technologies, as well as reliable partners. As the pace of vaccination increases every day and work on effective therapeutics intensifies, we can look ahead with more optimism and confidence” she said.

The EC said that the May 20 contract with the BioNTech-Pfizer alliance builds upon the broad portfolio of vaccines to be produced in Europe, including the already signed contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, Curevac and Moderna and BioNTech/Pfizer itself. T

The Commission has granted conditional marketing authorisation for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca and Johnson and Johnson.

“This diversified vaccines portfolio ensures Europe has access to enough doses to immunise its whole population including for the variant viruses,” the EC said.

(Photo: EC Audiovisual Service)

For the rest of The Sofia Globe’s continuing coverage of the Covid-19 situation, please click here.

The Sofia Globe’s coverage of the Covid-19 situation in Bulgaria is supported by the Embassies of Switzerland and Finland.

Please support independent journalism by clicking on the orange button below. For as little as three euro a month or the equivalent in other currencies, you can support The Sofia Globe via and get access to exclusive subscriber-only content:

Become a Patron!

The Sofia Globe staff

The Sofia Globe - the Sofia-based fully independent English-language news and features website, covering Bulgaria, the Balkans and the EU. Sign up to subscribe to's daily bulletin through the form on our homepage.